Abstract
During the past 40 years, somatostatin (SST) has been a subject of intensive research. Apart from its substantial role in the neuroendocrine system, due to its dense localization in various areas in the brain, its functions as a neuromodulator have also been thoroughly investigated. Increasing evidence suggests that SST plays a crucial role in memory and cognition. Synthetic forms, biologically active peptide sequences, SST receptor agonists and SST depleting agents have been applied in animal models and in human studies of a number of neuropsychiatric disorders. The translation of experimental data into clinical use could provide novel therapies in neurodegenerative disorders involving cognitive dysfunctions. However in view of the controversial data reported concerning the different roles of the SST receptor subtypes, and the lack of SST analogs that are able to cross diffusion barriers and act selectively at these receptor subtypes, broader clinical use of SST analogs as cognitive enhancers is limited. This review covers the whole range of available experimental results relating to the behavioral effects of SST, and highlights the potential for further investigations.
Keywords: Alzheimer’s disease, animal models, cognition, Huntington’s disease, learning, memory, Parkinson’s disease, somatostatin
Mini-Reviews in Medicinal Chemistry
Title:Somatostatin and Cognitive Function in Neurodegenerative Disorders
Volume: 13 Issue: 1
Author(s): Gabor Tuboly and Laszlo Vecsei
Affiliation:
Keywords: Alzheimer’s disease, animal models, cognition, Huntington’s disease, learning, memory, Parkinson’s disease, somatostatin
Abstract: During the past 40 years, somatostatin (SST) has been a subject of intensive research. Apart from its substantial role in the neuroendocrine system, due to its dense localization in various areas in the brain, its functions as a neuromodulator have also been thoroughly investigated. Increasing evidence suggests that SST plays a crucial role in memory and cognition. Synthetic forms, biologically active peptide sequences, SST receptor agonists and SST depleting agents have been applied in animal models and in human studies of a number of neuropsychiatric disorders. The translation of experimental data into clinical use could provide novel therapies in neurodegenerative disorders involving cognitive dysfunctions. However in view of the controversial data reported concerning the different roles of the SST receptor subtypes, and the lack of SST analogs that are able to cross diffusion barriers and act selectively at these receptor subtypes, broader clinical use of SST analogs as cognitive enhancers is limited. This review covers the whole range of available experimental results relating to the behavioral effects of SST, and highlights the potential for further investigations.
Export Options
About this article
Cite this article as:
Tuboly Gabor and Vecsei Laszlo, Somatostatin and Cognitive Function in Neurodegenerative Disorders, Mini-Reviews in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1389557511307010034
DOI https://dx.doi.org/10.2174/1389557511307010034 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Body’s Energy Engine))
CNS & Neurological Disorders - Drug Targets Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
Current Medicinal Chemistry Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics SUBJECT INDEX TO VOLUME 1
Current Genomics Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Metabolic Control of Glia-Mediated Neuroinflammation
Current Alzheimer Research Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry